Compare Direxion Daily TSLA Bull 2X Shares (TSLL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily TSLA Bull 2X Shares vs Zoetis Inc — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $8, while Zoetis Inc trades at $73.15 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Direxion Daily TSLA Bull 2X Shares pays none. Which is the better fit depends on your goals.
| TSLL | ZTS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $23.03 | $156.76 |
52-Week Low | $6.74 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, is trading at $7.975, down 2.86% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The ETF aims to deliver twice Tesla's daily returns, amplifying volatility in a stock known for significant price swings. Recent news highlights its sensitivity to Tesla's performance, with Q2 earnings on July 22, 2026, potentially driving sharp moves.
The outlook for TSLL is highly speculative, tied directly to Tesla's stock volatility, offering leveraged upside but with elevated risk of losses even in rising markets. Investors face risks from daily rebalancing decay, market sentiment shifts, and Tesla-specific developments, requiring caution due to the ETF's non-traditional structure and lack of fundamental company metrics.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
